Spyre Therapeutics
SYRE
SYRE
33 hedge funds and large institutions have $30.4M invested in Spyre Therapeutics in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
21% less capital invested
Capital invested by funds: $38.5M → $30.4M (-$8.06M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Holders
33
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$8.81M | |
| 2 | +$5.24M | |
| 3 | +$940K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$553K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$82K |
Top Sellers
| 1 | -$320K | |
| 2 | -$223K | |
| 3 | -$91K | |
| 4 |
Renaissance Technologies
New York
|
-$60.8K |
| 5 |
Bank of New York Mellon
New York
|
-$43.1K |